Drug Monograph

Drug Name: **Eprontia™ (topiramate) solution**
Drug Class: **Central Nervous System: Anticonvulsants**
Prepared For: MO HealthNet
Prepared By: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Eprontia is available in a 473 mL bottle containing 25 mg/mL topiramate oral solution.
Manufacturer:	Manufactured by: Tulex Pharmaceuticals, Inc., Cranbury Township, NJ 08512.
Indications:	Eprontia is indicated: • As initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older • As adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older • For the preventive treatment of migraine in patients 12 years and older.
Costs:	$665 per 473 mL Wholesale Acquisition Cost
Summary of Findings:	The MO HealthNet Division recommends prior authorization status for this product.
Status Recommendation:	☐ Clinical Edit ☒ PA Required ☐ Open Access ☐ PDL
Type of PA Criteria:	☒ Appropriate Indications ☐ Non-Preferred ☐ No PA Required ☐ Preferred

Prepared by: April Ash, PharmD
Date: December 30, 2021